Molbio Diagnostics IPO: Price Band ₹768–807, Live GMP & Healthcare Review

1.Company Overview

Molbio Diagnostics Limited, creator of the patented Truenat point-of-care portable Real-Time PCR testing platform, opens its ₹939.7 Crore IPO on August 10, 2026.

Molbio's diagnostic devices are widely deployed for rapid molecular testing of tuberculosis, COVID-19, hepatitis, and vector-borne diseases.

2.Issue Details at a Glance

3.Technology & Market Position

• Platform: patented Truenat point-of-care portable Real-Time PCR testing
• Applications: tuberculosis, COVID-19, hepatitis and vector-borne disease testing
• Demand drivers: strong global export demand and WHO endorsement

4.Molbio Diagnostics IPO GMP Today

Grey market premium for Molbio Diagnostics is tracked through the bidding window. GMP is informal and unregulated, is not published by any exchange, and can change before listing.

5.How to Apply for Molbio Diagnostics IPO

1. 1Open IPOGMPTracker or use your broker's app or net banking ASBA facility.
2. 2Search for "Molbio Diagnostics IPO" and select it from the list of current issues.
3. 3Choose your demat account and enter your bid quantity in multiples of the lot size stated in the RHP, at a price within the ₹768–807 band (or bid at cut-off, if eligible).
4. 4Submit the application and approve the UPI mandate request — funds stay blocked and are debited only on allotment.

6.How to Track Subscription & Allotment

• Live subscription: Track category-wise bidding on the IPO subscription status page
• Allotment status: Check your application on the IPO allotment status page
• More issues: Browse current IPOs and the IPO event calendar

7.Conclusion

Molbio Diagnostics opens on August 10, 2026 at ₹768–807 per share for a ₹939.7 Crore issue. Read the offer documents in full and consult a qualified adviser before applying — nothing here is investment advice.